This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A team of Israeli researchers conducted a randomized placebo-controlled clinical trial to assess the safety and efficacy of a novel, metered-dose cannabis inhaler in 27 patients with chronic pain. Chronic pain is the most commonly reported qualifying condition among medical cannabis patients enrolled in state-specific access programs.
Three new laws intended to expand patient access to and the therapeutic value of Virginia’s medical cannabis program take effect July 1, 2019. “This year, my focus was on program improvements to further expand both access and therapeutic value to benefit the health and well-being of all Virginians.” SCHOOL-USE.
The final goal is to introduce medicinal cannabis products to the pharmaceutical drug market. We know that the plant has powerful potential medical effects, but it clearly needs more refinement, more research and more data,” stated Groff, who envisions a future where patients can easily access ailment-targeted cannabis meds.
Biotech startup to bring safety and efficacy to the emerging psychedelic industry, brings on University of Michigan Researcher as Chief Science Officer. Psycheceutical is on a mission to bring safety and efficacy to psychedelic compounds with patented delivery systems designed specifically for this new class of medications.”
We are delighted by today’s decision from the MHRA for this new indication, which represents a significant step forward for TSC patients in the UK, many of whom may benefit from this new treatment,” said Chris Tovey , Executive Vice President, Chief Operating Officer and Managing Director, Europe & International at Jazz Pharmaceuticals.
Legislation is pending, Senate Bill 165, to establish a medical marijuana access program for qualified patients with a physician’s recommendation to access medical marijuana from licensed retail outlets. Send a message to your lawmakers in support of medical marijuana access. AL resident? NH resident? OK resident?
Can businesses cultivate cannabis for pharmaceutical research? Comply with relevant workplace health and safety legislation. Yesespecially in safety-sensitive industries (mining, transport, healthcare). Employers must balance workplace safety with disability discrimination laws. Obtain TGA and state regulatory approvals.
with unknown pharmacological and safety profiles.” These hemp hustlers are in it for the money, making active pharmaceutical ingredients using process chemistry and producing formulated end-products like vape pens, gummies, and sodas in garages, airplane hangars, basements, and warehouses. Dr. Mark A.
In general, I think that botanical medicine is safer than pharmaceutical medicine, that the chances of causing harm are much less. So just on safety alone, it’s worth using it. I include pharmaceutical drugs in that category. In general, I think that botanical medicine is safer than pharmaceutical medicine.
There are currently five “pharmaceutical processor” permit holders in Virginia, and they’re about to open for business. In Virginia, these families were simply asking to be able to possess the medicines they were able to access in other states. This interview has been edited for clarity and space. We need to do more.
Legislation is pending, House Bill 1272, to expand access to medical cannabis in North Dakota. Update : The Criminal Justice and Public Safety Committee will hold an executive session for HB 399 on 1/17 at 11am. Legislation is pending, House Bill 350, to expand medical cannabis access. ND resident? NH resident? NH resident?
179: The VA Medicinal Cannabis Research Act of 2019 to facilitate federally-sponsored clinical research into the safety and efficacy of medical cannabis among veterans. Legislation is pending, House Bill 1150, to expand the state’s nascent medical cannabis access law. HI resident? IA resident? MO resident? North Dakota. NH resident?
.–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. The Phase 2 TSC trial, the CALM trial, was an open-label trial to evaluate the safety and tolerability of adjunctive ganaxolone treatment in patients with seizures associated with TSC. About Marinus Pharmaceuticals. 484-253-6792.
A United Kingdom police chief proposed a novel idea this January: Allow drug-dependent inmates access to free cannabis to help them overcome opioid addiction. This creates a situation where state detention facilities — even where cannabis is legal — do not allow inmates access to medical cannabis because it violates federal law.
5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. Accessed July 25, 2021. Accessed October 17, 2022.
Click here to email your lawmakers in support of banking access. Legislation is pending, House Bill 5442, to expand patients’ access to medical cannabis in Connecticut. Legislation is pending, SF 77, to expand access to certain medical cannabis products in Iowa. CA resident? CT resident? HI resident? IA resident?
People are increasingly using ketamine for ailments that resist treatment through traditional pharmaceutical drugs. “ Off-label use ” (which is extremely common) is: the use of pharmaceutical drugs for an unapproved indication or in an unapproved age group, dosage, or route of administration.
Legislation is pending, House Bill 268 and House Bill 528, to allow those convicted of simple marijuana possession to petition the court to restrict access to their records. Send a message to your lawmakers in support of access to edibles. Send a message to your lawmakers in opposition to arbitrary THC limits. GA resident? HI resident?
’s medical cannabis program come on the heels of a previously enacted emergency amendment focused on senior citizens: The Medical Marijuana Patient Access Extension Emergency Amendment Act of 2022 allowed D.C. The State of Patients’ Rights and Access in America Today. These changes to D.C.’s
By legalizing MMJ, the state has facilitated access to a natural and potentially life-changing treatment option for patients suffering from various medical conditions. The industry also encourages the development of novel pharmaceuticals and treatments, creating opportunities for Maryland residents to access cutting-edge healthcare options.
The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.
12, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq: GWPH), the world leader in the science, development, and commercialization of cannabinoid prescription medicines, today reported preliminary, unaudited net product sales for the fourth quarter and full-year 2019 and key priorities for 2020. Enquiries: GW Pharmaceuticals plc.
Today, she maintains a discreet, effective regimen that has reduced her pharmaceutical intake by over half. The childproof containers can be challenging, but the medication itself is accessible.” Initially hesitant due to personal perceptions, Elena discovered marijuana THC edibles that transformed her treatment experience.
Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. Santé Cannabis is at the forefront of safe and supported patient access to complementary medicines. ABOUT SANTÉ CANNABIS.
With the filed patent on entactogenic compounds, the company would be able to further develop treatments that precisely match the needs of medical practice, by reducing harm and improving the safety profile when compared to traditional MDMA.
Other states have gone beyond just medical access and have also legalized retail cannabis markets for adult consumers. Please don’t further the lie by voting for any form of legalization beyond the pharmaceutical remedies already available under state law.” ” State Doctors Oppose Legalization in Alabama.
The experiment will allow participating companies to import cannabis and the companies who wish to participate in the experiment will be obliged to give participants free medical cannabis which has to comply with the pharmaceutical standards and good manufacturing practice. .
Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Google Translation.
This agreement will provide access to Evotec’s technology platform to further accelerate the development of OCT461201 towards phase 1 clinical trials aimed at demonstrating its safety and tolerability by utilising its “INDiGO” programme, an integrated drug development process for expediting early drug candidates to the clinical trial stage.
BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc.
As a company that takes pride in their safety level, Matter produces quality, effective, and consistent products that can provide therapeutic relief to those suffering from chronic medical conditions. The brand’s growers are pharmaceutical experts who think of the user’s best needs every step of the way. Abx – AbsoluteXrracts.
We are in a mental health crisis and its critical to ensure that we conduct clinical trials to demonstrate safety, and efficacy up to and including phase 3 large scale clinical trials. Extensive early phase experience with appropriate safety oversight and early phase clinic.
Although CBD’s full medical benefits and safety profile are still under review by researchers and appropriate regulators, the compound has successfully scaled several legal roadblocks. Even more, CBD is the first FDA-approved pharmaceutical drug for two rare forms of epileptic seizures in kids.
Medical cannabis and psychedelics are being increasingly recognised by health professionals for their superior safety and efficacy compared to conventional pharmaceuticals. Due to its illegality and stigma, patients greatly suffered from an inability to access this medicine.
The study, titled Pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: A randomized, double-blinded, placebo-controlled trial , was first published by NORML. Pain intensity and safety parameters were recorded on a 10-cm visual analogue scale (VAS) at pre-defined time points.
Being a member of the Drug Science Medical Cannabis Working Group, Schlag’s current research focuses on the controversies surrounding medical cannabis and the application of MultiCriteria-Decision-Analysis to assess benefits and safety. Deepak Anand. Deepak Anand is recognised as a thought leader in the global cannabis space.
I have an extensive background in healthcare and have worked in the community, aged care and palliative care sectors as well the corporate (pharmaceutical and insurance) sectors. Road Safety laws to be amended to allow for a defence for medicinal users. Click on image to watch on you tube.
The campaign manager of the ‘Yes on 109’ campaign that helped see the measure passed, Sam Chapman, told media sources, “There’s a huge breadth of expertise on this board from harm reduction experts to folks that have experience working with different populations that stand to benefit from having access to psilocybin therapy.
Ensuring the potency and safety of cannabis edibles and oils is paramount for patients reliant on their therapeutic benefits. These pharmaceutical-grade formulations provide patients with a discreet and easy-to-administer method of ingestion. Properly drying or dehydrating ingredients can help mitigate this risk and prolong shelf life.
Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. But if that doctor has access to information from 40,000 patients it’s a different story.
Unfortunately, the conventional pharmaceuticals used to treat these symptoms have significant side effects leaving families with no solution. Although this experimental approach can be intimidating for many, it is important to note that cannabis has an excellent safety profile and is well tolerated by most.
Moreover much of the research done has focused on synthetic pharmaceutical grade cannabinoids developed by pharmaceutical companies. Cannabis is still very much illegal in many countries, which makes it very challenging for researchers to gain access to materials, money, and opportunities to conduct research in the first place.
“There is significant real-world and clinical evidence supporting the safety and effectiveness of cannabis-based medicinal products,” said said Dr. Mark Ware, chief medical officer at Canopy. It will begin by lobbying UK patient groups and doctors and launching a physician education program to open research to UK docs.
Each state and territory has different regulations regarding how medicinal cannabis can be accessed, with some jurisdictions making it easier than others. The Therapeutic Goods Administration oversees approvals for medicinal cannabis products, and most patients require approval through the Special Access Scheme.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content